Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Plasma volume

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    787 result(s) found for: Plasma volume. Displaying page 10 of 40.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    EudraCT Number: 2014-004928-21 Sponsor Protocol Number: CINC424A2353 Start Date*: 2016-01-27
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations
    Medical condition: Early Myelofibrosis patients with high molecular risk mutations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) BE (Prematurely Ended) HU (Completed) GR (Completed) FR (Prematurely Ended) PT (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004914-79 Sponsor Protocol Number: CA017-003 Start Date*: 2016-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001910-33 Sponsor Protocol Number: AGAL02603 Start Date*: 2007-12-05
    Sponsor Name:Genzyme Europe BV
    Full Title: A Multicenter, Multinational Study of the Effects of Fabrazyme® (agalsidase beta) Treatment on Lactation and Infants
    Medical condition: Fabry disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016016 Fabry's disease PT
    Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003458-26 Sponsor Protocol Number: CSLCT-HDL-12-77 Start Date*: 2014-07-15
    Sponsor Name:CSL Behring LLC
    Full Title: A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial I...
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) CZ (Completed) AT (Completed) DK (Completed) HU (Completed) NL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000438-35 Sponsor Protocol Number: CL 0600-004 Start Date*: 2004-09-30
    Sponsor Name:NPS Allelix Corporation
    Full Title: A study of the Efficacy and Safety of Teduglutide in subjects with Parenteral Nutritional Dependant Short Bowel Syndrome
    Medical condition: Short Bowel Syndrome (SBS) refers to the clinical situation whereby a significant reduction in the absorptive capacity of the intestine results from inadequate anatomical or functional length of re...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001345-14 Sponsor Protocol Number: ZOLCAR17001 Start Date*: 2018-08-03
    Sponsor Name:Ziekenhuis Oost-Limburg Autonome Verzorgingsinstelling
    Full Title: A multi-center, randomized, double-blind, phase IV clinical trial on the diuretic effects of Acetazolamide (Diamox ®) in patients with Decompensated heart failure and Volume OveRload.
    Medical condition: The study population will consist of patients hospitalized with decompensated heart failure and demonstrating at least one clinical sign of volume overload.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019284 Heart failure, congestive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002849-38 Sponsor Protocol Number: AQ-PRO-005 Start Date*: 2020-09-08
    Sponsor Name:Aquilon Pharmaceuticals
    Full Title: A prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the safety, pharmacodynamics, pharmacokinetics, and preliminary...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003197-24 Sponsor Protocol Number: PL8177-106 Start Date*: 2020-03-16
    Sponsor Name:Palatin Technologies, Inc.
    Full Title: A Phase 2, Randomized, 3-Arm Parallel Group, Placebo and Active-Controlled Study of the Effect of PL8177 Administered via Subcutaneous Injection in Healthy Male Volunteers on Inflammatory Onset and...
    Medical condition: Inflammatory Onset and Resolution
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004867 10053414 Application site blister LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000138-12 Sponsor Protocol Number: ALADIN2 Start Date*: 2011-04-04
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosoma...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004797-18 Sponsor Protocol Number: Start Date*: 2017-06-26
    Sponsor Name:Imperial College London
    Full Title: Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients.
    Medical condition: Intestinal failure with an underlying aetiology of short bowel
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000916-75 Sponsor Protocol Number: REC-DUT-002 Start Date*: 2018-06-07
    Sponsor Name:RECARDIO Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
    Medical condition: Acute myocardial infarction, acute myocardial ischemia, STEMI ST elevation myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) BE (Completed) NL (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005426-18 Sponsor Protocol Number: DECONGEST_v1.0 Start Date*: 2022-03-02
    Sponsor Name:UZ Brussel
    Full Title: Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment
    Medical condition: Acute Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002684-29 Sponsor Protocol Number: IP-001-21 Start Date*: 2023-07-10
    Sponsor Name:IPERBOREAL PHARMA S.R.L.
    Full Title: A Study of GlucoThera Plus for PeRitoneal DiAlysis in Children.
    Medical condition: End-Stage Renal Disease (ESRD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038359 - Renal and urinary disorders 10077512 End stage renal disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004343-23 Sponsor Protocol Number: IG0902 Start Date*: 2018-03-20
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: Studio per indagare le proprietà farmacocinetiche (per vedere quanto è attivo il farmaco di studio nel sangue e quanto tempo ci vuole per il farmaco di studio per uscire dal sangue), l'efficacia e ...
    Medical condition: Congenital Afibrinogenemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10052651 Afibrinogenaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006768-53 Sponsor Protocol Number: A8441003 Start Date*: 2007-01-26
    Sponsor Name:Pfizer Global Research & Development
    Full Title: A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE ...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003886-15 Sponsor Protocol Number: TELIT L 01747 Start Date*: 2006-09-12
    Sponsor Name:SANOFI-AVENTIS S.P.A
    Full Title: Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dos...
    Medical condition: Acute exacerbation of chronic-obstructive pulmonary disease.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029978 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005063-28 Sponsor Protocol Number: Emend2 Start Date*: 2013-10-02
    Sponsor Name:University of Gothenburg
    Full Title: Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant
    Medical condition: End stage renal disease under treatment with peritoneal dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003027-30 Sponsor Protocol Number: IIBSP-ALB-2017-72 Start Date*: 2017-11-27
    Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau
    Full Title: Influence of albumin on the development of acute renal dysfunction associated with cardiac surgery under extracorporeal circulation
    Medical condition: Renal function
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004488-14 Sponsor Protocol Number: PDC01-0204 Start Date*: 2021-02-10
    Sponsor Name:Cessatech A/S
    Full Title: Bioavailability study of intranasal sufentanil/ketamine fixed combination in healthy volunteers
    Medical condition: Not applicable - healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    22.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003576-12 Sponsor Protocol Number: OC5-OL-02 Start Date*: 2019-01-23
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 6  7  8  9  10  11  12  13  14  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 22 07:14:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA